查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930143

全球前列腺癌荷爾蒙療法市場：市場規模、佔有率、成長率、行業分析、依類型、應用和地區劃分的考察、未來預測（2026-2034）

Prostate Cancer Hormone Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

前列腺癌荷爾蒙療法市場的成長因素

受前列腺癌發病率上升、老年男性診斷率增加以及荷爾蒙療法策略不斷進步的推動，全球前列腺癌荷爾蒙療法市場展現出強勁的成長潛力。根據2025年的報告年份，2025年市場規模達到204.4億美元，並在2026年成長至277.9億美元。在長期預測期內，預計到2034年，市場規模將達到驚人的831億美元，這反映了雄激素剝奪療法（ADT）和新一代激素類藥物的廣泛應用。

荷爾蒙療法仍然是前列腺癌治療的基石，尤其是在晚期和轉移性疾病階段。前列腺癌的生長受到睪固酮等雄性激素的強烈影響，抑製或阻斷這些荷爾蒙的治療方法可以顯著延緩疾病進展。由於其臨床療效，荷爾蒙療法廣泛用作轉移性前列腺癌的第一線治療，與其他療法聯合使用的情況也日益增多。

市場概覽及關鍵洞察

到2025年，北美將佔據前列腺癌荷爾蒙療法市場52.30%的佔有率，區域市場規模將達到106.9億美元。這一優勢得益於強有力的醫療保險政策、先進的腫瘤治療基礎設施以及創新荷爾蒙療法的早期應用。美國憑藉高額的研發投入、強大的臨床試驗管道以及新藥頻繁獲得監管部門批准，在北美市場佔據領先地位。

歐洲市場佔有率位居第二，這主要得益於成本效益方面的監管批准以及公眾對前列腺癌的高度認知。亞太地區預計將實現最快成長，這主要得益於人口老化加劇、攝護腺癌發病率上升以及日本和中國等國家監管審批速度加快。

市場動態

市場驅動因素

荷爾蒙療法的進步是推動市場成長的主要因素。隨著時間的推移，患者往往會對傳統的雄性激素剝奪療法產生抗藥性，這促使製藥公司開發雄性激素受體抑制劑和聯合療法，以提高存活率。先進療法的持續監管審批擴大治療選擇範圍，無論疾病處於哪個階段。

市場限制因子

荷爾蒙療法抗藥性的產生是主要的限制因素。在長期治療過程中，前列腺癌細胞會透過雄性激素受體突變和替代雄性激素合成途徑來適應。這些機制會降低治療效果，需要額外的治療干預，並影響患者的長期治療順從性。

市場挑戰

荷爾蒙療法會帶來一些副作用，例如勃起功能障礙、性慾減退和疲勞。臨床資料顯示，超過 80.0%的接受雄性激素剝奪療法（ADT）的患者會出現勃起功能障礙，約 64.0%的患者會出現性慾減退。這些副作用會顯著影響患者的生活品質，並可能影響治療順從性。

市場機會

聯合療法的研發，特別是將雄性激素剝奪療法（ADT）與 PARP 抑制劑或新型標靶藥物聯合使用的療法，蘊藏著巨大的成長機會。臨床試驗結果表明，聯合療法能夠提高存活率並降低死亡風險，這正推動著聯合治療策略的更廣泛應用。

市場趨勢

一個值得關注的市場趨勢是，長效緩釋製劑的核准和應用日益增多。這些長效療法透過減少給藥頻率和最大限度地減少荷爾蒙波動，提高了治療依從性，尤其是在老年患者中。多個地區的監管機構支持這些創新，以加強以患者為中心的前列腺癌治療。

市場區隔分析

依藥物類別

促性腺激素釋放激素（GnRH）促效劑細分市場佔據了最大的市場佔有率，這得益於其在抑制睪固酮方面的顯著療效和廣泛的臨床應用。由於睪酮抑制速度更快以及監管審批的增加，GnRH受體拮抗劑預計將快速成長。雄性激素受體抑制劑市場也隨著核准適應症的增加而顯著擴張。

依疾病狀態劃分

轉移性去勢抵抗性攝護腺癌（mCRPC）市場佔最大佔有率，這主要得益於該疾病的高負擔和頻繁的監管審批。隨著各公司將藥物適應症擴展到更早期的疾病階段，非轉移性前列腺癌市場預計將成長更快。

依給藥途徑劃分

口服給藥因其便利性、更高的依從性以及仿製藥的廣泛普及而佔據市場主導地位。腸外給藥雖然市場佔有率較小，但透過進行中的臨床試驗，其重要性日益凸顯。

依通路劃分

醫院藥局憑藉其專業的監管和獲得先進治療方案的管道，保持著領先的市場佔有率。同時，隨著數位化進程的推進，線上藥局的市場佔有率也在不斷成長。

2025年版前列腺癌激素療法市場報告提供了2025年、2026年和2034年的全面市場規模和價值預測，並深入分析了市場動態、趨勢、細分、區域表現、競爭格局和最新發展。該分析重點關注監管環境、荷爾蒙療法創新以及不斷演變的治療模式，這些因素共同塑造了市場的長期擴張。

北美在2025年以52.30%的市場佔有率引領市場，凸顯了其先進的醫療基礎設施、有利的償付政策和強大的研究生態系統的重要性。同時，歐洲和亞太地區也憑藉其經濟有效的治療方案和不斷擴大的患者群體，為市場做出了顯著貢獻。儘管存在治療抗藥性和治療相關副作用等挑戰，但持續的研究、監管審批以及向長效製劑和聯合療法的轉變緩解這些局限性。總體而言，創新、適應症的擴大以及前列腺癌在全球範圍內日益嚴重的負擔，為2034年之前的長期成長創造了有利的市場環境。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 主要國家和地區的攝護腺癌盛行率（2025年）
  • 主要公司的研發管線分析
  • 替代療法概述
  • 市場上主要的新創企業
  • 主要公司的新產品發布
  • 關鍵產業趨勢：併購、業務合作等
  • 新冠疫情對市場的影響

第5章 全球前列腺癌荷爾蒙療法市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依藥物類別劃分
    • 雄性激素受體抑制劑
    • 促性腺激素釋放激素（GnRH）促效劑
    • 促性腺激素釋放激素（GnRH）受體拮抗劑
    • 其他
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測：依疾病狀態劃分
    • 轉移性去勢抵抗性攝護腺癌
    • 非轉移性去勢抵抗性攝護腺癌
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 藥局和零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美前列腺癌荷爾蒙療法市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲前列腺癌激素療法市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第8章 亞太地區前列腺癌激素療法市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章 拉丁美洲前列腺癌激素療法市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第10章 中東與非洲前列腺癌激素療法市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • GCC國家
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 全球市場佔有率分析（2025）
  • 公司簡介
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Johnson &Johnson Services, Inc.
    • Ferring Pharmaceuticals Inc.
    • Sumitomo Pharma Co., Ltd.（Myovant Sciences GmbH）
    • AbbVie Inc.
    • AstraZeneca
    • Accord BioPharma, Inc.
    • Bayer AG
Product Code: FBI112836

Growth Factors of prostate cancer hormone therapy Market

The global prostate cancer hormone therapy market demonstrates strong growth potential, driven by the rising prevalence of prostate cancer, increasing diagnosis rates among the aging male population, and continuous advancements in hormonal treatment strategies. As per the 2025 report year, the market was valued at USD 20.44 billion in 2025 and is projected to expand to USD 27.79 billion in 2026. Over the long-term forecast horizon, the market is expected to reach a substantial value of USD 83.1 billion by 2034, reflecting widespread adoption of androgen deprivation therapy (ADT) and next-generation hormone-based drugs.

Hormone therapy remains a cornerstone in prostate cancer treatment, particularly for advanced and metastatic disease stages. Prostate cancer growth is strongly influenced by androgens such as testosterone, and therapies that suppress or block these hormones significantly slow disease progression. Due to its clinical effectiveness, hormone therapy is commonly used as a first-line treatment in metastatic prostate cancer and increasingly in combination with other therapeutic modalities.

Market Overview and Key Insights

In 2025, North America dominated the prostate cancer hormone therapy market with a 52.30% share, accounting for a regional market value of USD 10.69 billion. This dominance is supported by strong reimbursement policies, advanced oncology infrastructure, and early adoption of innovative hormone therapies. The United States leads the region due to high research investments, robust clinical trial pipelines, and frequent regulatory approvals for novel drugs.

Europe holds the second-largest share, supported by cost-effectiveness endorsements from healthcare authorities and high disease awareness. The Asia Pacific region is projected to be the fastest-growing, driven by an expanding geriatric population, increasing prostate cancer incidence, and accelerating regulatory approvals in countries such as Japan and China.

Market Dynamics

Market Drivers

Advancements in hormonal therapies are a major driver of market growth. Traditional androgen deprivation therapy often leads to resistance over time, prompting pharmaceutical companies to develop androgen receptor inhibitors and combination therapies that improve survival outcomes. Regulatory approvals for advanced therapies continue to strengthen treatment availability across disease stages.

Market Restraints

A key restraint is the development of resistance to hormone therapy. Over prolonged treatment periods, prostate cancer cells adapt through androgen receptor mutations or alternative androgen synthesis pathways. These mechanisms reduce treatment efficacy and necessitate additional therapeutic interventions, impacting long-term treatment continuity.

Market Challenges

Hormone therapy is associated with adverse effects such as erectile dysfunction, reduced libido, and fatigue. Clinical data indicate that over 80.0% of patients undergoing ADT experience erectile dysfunction, while approximately 64.0% report loss of sexual desire. These side effects can significantly affect patient quality of life and influence therapy adherence.

Market Opportunities

Research and development of combination therapies, particularly pairing ADT with PARP inhibitors or novel targeted agents, presents strong growth opportunities. Clinical trial results demonstrating improved survival and reduced mortality risk are encouraging broader adoption of combination treatment strategies.

Market Trends

A prominent trend in the market is the increasing approval and adoption of long-acting depot formulations. These sustained-release therapies improve patient adherence by reducing dosing frequency and minimizing hormonal fluctuations, especially in elderly patients. Regulatory agencies across multiple regions are supporting such innovations to enhance patient-centric prostate cancer care.

Segmentation Analysis

By Drug Class

The Gonadotropin-Releasing Hormone (GnRH) agonists segment held the largest market share due to proven effectiveness in testosterone suppression and widespread clinical use. GnRH receptor antagonists are expected to grow rapidly owing to faster testosterone suppression and rising regulatory approvals. The androgen receptor inhibitors segment is also expanding significantly due to increasing indication approvals.

By Disease State

The metastatic castration-resistant prostate cancer (mCRPC) segment accounts for the largest share, driven by high disease burden and frequent regulatory approvals. The non-metastatic segment is anticipated to grow faster as companies expand drug indications to earlier disease stages.

By Route of Administration

The oral route dominates the market due to convenience, improved adherence, and increasing availability of generic drugs. Parenteral therapies hold a smaller share but continue to gain relevance through ongoing clinical trials.

By Distribution Channel

Hospital pharmacies maintain a leading share due to specialist oversight and access to advanced therapies, while online pharmacies are gaining traction with rising digital adoption.

Competitive Landscape

The prostate cancer hormone therapy market is moderately consolidated, with key players including Astellas Pharma Inc., Pfizer Inc., Bayer AG, and Johnson & Johnson Services, Inc.. These companies continue to strengthen their market positions through product launches, regulatory approvals, acquisitions, and strategic collaborations aimed at expanding global access to advanced hormone therapies.

Report Scope

The 2025 prostate cancer hormone therapy market report provides comprehensive coverage of market size and value for 2025, 2026, and 2034, along with detailed insights into market dynamics, trends, segmentation, regional performance, competitive landscape, and recent industry developments. The analysis emphasizes regulatory progress, innovation in hormone therapy, and the evolving treatment paradigm shaping long-term market expansion.

Conclusion

The prostate cancer hormone therapy market is set for sustained and robust expansion over the forecast period, supported by a strong clinical foundation and continuous therapeutic innovation. With a market value of USD 20.44 billion in 2025, projected to rise to USD 27.79 billion in 2026 and further escalate to USD 83.1 billion by 2034, the market outlook reflects the growing dependence on hormone-based treatments across multiple stages of prostate cancer. The central role of androgen deprivation therapy, combined with the rapid uptake of next-generation androgen receptor inhibitors and combination regimens, continues to redefine treatment standards.

North America's leadership, holding 52.30% market share in 2025, underscores the importance of advanced healthcare infrastructure, favorable reimbursement policies, and strong research ecosystems, while Europe and Asia Pacific contribute significantly through cost-effective treatment access and expanding patient populations. Despite challenges such as therapy resistance and treatment-related adverse effects, ongoing research, regulatory approvals, and the shift toward long-acting formulations and combination therapies are mitigating these limitations. Overall, the market is well-positioned for long-term growth through 2034, driven by innovation, expanding indications, and the increasing global burden of prostate cancer.

Segmentation By Drug Class

  • Androgen Receptor Inhibitors
  • Gonadotropin Releasing Hormone (GnRH) Agonist
  • Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Disease State

  • Metastatic Castration-Resistant Prostate Cancer
  • Non-Metastatic Castration-Resistant Prostate Cancer

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. Key Start-ups in the Market
  • 4.5. New Product Launches, by Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.7. Impact of COVID-19 on the Market

5. Global Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Androgen Receptor Inhibitors
    • 5.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 5.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Disease State
    • 5.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 5.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Androgen Receptor Inhibitors
    • 6.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 6.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Disease State
    • 6.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 6.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Androgen Receptor Inhibitors
    • 7.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 7.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Disease State
    • 7.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 7.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Androgen Receptor Inhibitors
    • 8.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 8.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Disease State
    • 8.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 8.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Androgen Receptor Inhibitors
    • 9.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 9.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Disease State
    • 9.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 9.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Androgen Receptor Inhibitors
    • 10.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 10.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Disease State
    • 10.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 10.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Drug Stores & Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Astellas Pharma Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Ferring Pharmaceuticals Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. AbbVie Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AstraZeneca
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Accord BioPharma, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bayer AG
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 4: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 5: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 8: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 9: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 10: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 12: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 14: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 15: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 17: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 18: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 19: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 20: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 22: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 24: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 25: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 27: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 28: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 29: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 30: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Prostate Cancer Hormone Therapy Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025 & 2034
  • Figure 5: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Prostate Cancer Hormone Therapy Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 8: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 9: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 10: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 11: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 12: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
  • Figure 13: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Prostate Cancer Hormone Therapy Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Prostate Cancer Hormone Therapy Market Value Share (%), By Country, 2025
  • Figure 17: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 18: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 19: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 20: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 21: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 22: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
  • Figure 23: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 28: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 29: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 30: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 31: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 32: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
  • Figure 33: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion),by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 39: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 40: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 41: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 42: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
  • Figure 43: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 48: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 49: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 50: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 51: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 52: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
  • Figure 53: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2025

Figure 57: Global Prostate Cancer Hormone Therapy Market Share (%), By Company, 2025